Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
Cancer Chemotherapy and Pharmacology|March 15, 2012
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancerMaiko Asakuma, Michiko Yamamoto, Mayuko Wada, et al.Investigational New Drugs|November 7, 2020
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)Sakiko Otani, Jiichiro Sasaki, Yoshiro Nakahara, et al.Cancer Management and Research|December 28, 2018
Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung diseaseSatoshi Igawa, Noriko Nishinarita, Akira Takakura, et al.Oncology|September 14, 2022
The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung CancerMasashi Kasajima, Satoshi Igawa, Hiroya Manaka, et al.Thoracic Cancer|November 28, 2023
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study)Ou Yamaguchi, Keita Mori, Saori Takata, et al.Oncology Letters|July 12, 2017
Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation statusMikiko Ishihara, Satoshi Igawa, Jiichiro Sasaki, et al.Lung Cancer (Amsterdam, Netherlands)|September 18, 2021
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632Rintaro Noro, Satoshi Igawa, Akihiro Bessho, et al.Anticancer Research|December 6, 2015
Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910Kouzo Yamada, Haruhiro Saito, Tetsuro Kondo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2023
Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of ImmunotherapyMasahiro Torasawa, Hidehito Horinouchi, Shogo Nomura, et al.BMC Cancer|March 4, 2018
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016Satoshi Ikeda, Terufumi Kato, Takashi Ogura, et al.Pageof 11